-

Bruker Introduces Enhanced 3D Holographic Stimulation for Optogenetics on its Ultima 2Pplus Multiphoton Microscope

New NeuraLight 3D Ultra Module Expands Neuroscience Research Capabilities

MADISON, Wis.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the release of the NeuraLight 3D Ultra module to support advanced neuroscience and optogenetics research applications on Bruker’s Ultima multiphoton microscopes. NeuraLight 3D Ultra provides revolutionary 3D holographic photostimulation, specifically optimized for functional and large-scale studies of neural networks and brain computation. Building upon Bruker’s proprietary spatial light modulator (SLM) technology, the NeuraLight 3D Ultra module utilizes a new, larger liquid crystal chip that unlocks access to a larger field of view, improved targeting precision, and a market-leading speed of 600 hologram frames per second. Paired with the imaging capabilities of the Ultima 2Pplus microscope, it uniquely allows researchers to study mechanisms of behavior, perception, and disease at a larger scale and on a time scale that is reflective of the underlying biology.

“The system is performing very well in our laboratory, and we’re excited about the NeuraLight 3D Ultra’s speed, field of view, and resolution, which will enable us to perform all-optical interrogation experiments with greater fidelity and precision,” said Dr. Adam Packer, Wellcome Trust Sir Henry Dale Fellow at the University of Oxford. “The new format SLM and associated optical relays offer a better tradeoff between field of view and resolution that will be advantageous to addressing larger numbers of cells with improved accuracy. Additionally, the very fast update speed of the system will make it possible to activate sequences of cells at a high rate.”

“We are pleased to continue to develop innovative instrumentation in close collaboration with leaders in neuroscience research,” added Xiaomei Li, Ph.D., Vice President and General Manager for Bruker’s Fluorescence Microscopy Business. “With its largest in-class field of view in fast resonant mode, the Ultima 2Pplus microscope equipped with NeuraLight 3D Ultra is an optimized solution for all-optical interrogations of the brain.”

About NeuraLight 3D Ultra

The NeuraLight 3D Ultra is a module that strengthens and diversifies the functionality of Bruker’s Ultima multiphoton microscopes. These pioneering imaging systems have a proven track record of facilitating complex research in neuroscience and were first to enable simultaneous imaging and photostimulation of biological samples. NeuraLight 3D Ultra easily couples to one of the optical ports of the Ultima microscope to allow for independent imaging and simultaneous multicellular photostimulation. Comprehensive software enables user-friendly selection of targets in three dimensions with well-defined timing. The NeuraLight 3D Ultra module is available as an option for all new Ultima 2Pplus multiphoton microscopes and as an upgrade for selected models of microscopes produced since 2006. Ultima multiphoton systems equipped with NeuraLight 3D Ultra and paired with Bruker’s electrotunable lens option provide complete solutions for all-optical reading and writing of neuronal activity.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Justin Ward
Senior Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Stephen Hopkins
Content Marketing Manager
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Justin Ward
Senior Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Stephen Hopkins
Content Marketing Manager
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Introduces nVista 2P Miniature Microscope

SAN JOSE, Calif.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the launch of the nVista 2P miniature, two-photon microscope, a groundbreaking addition to the Inscopix product line for functional imaging of freely behaving animals. It leverages advanced two-photon fluorescence microscopy technology to enable high-resolution imaging at greater depths with 3D data reconstruction, providing researchers with unprecedented insights into neuronal activity. Featuring several innov...

Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring

MUNICH--(BUSINESS WIRE)--Bruker Corporation (NASDAQ: BRKR) today announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic kits for LC-MS/MS, HPLC, and ICP-MS assays. Financial details of the transaction were not disclosed. RECIPE has over 60 employees and continues to operate under the leadership of Managing Director Dr. Gerno...

Bruker Announces First Quarter 2025 Preliminary Revenue

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company’s earlier outlook and well ahead of consensus. This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.